NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3GlobeNewsWire • 11/02/22
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022GlobeNewsWire • 10/27/22
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment BankGlobeNewsWire • 10/18/22
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022Business Wire • 09/28/22
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022Business Wire • 09/22/22
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior ImmunotherapyBusiness Wire • 09/21/22
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024Business Wire • 09/12/22
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck CancerBusiness Wire • 09/07/22
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life SciencesBusiness Wire • 09/06/22
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022Business Wire • 08/31/22
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor IndicationsBusiness Wire • 06/05/22
Nanobiotix's (NBTX) CEO Laurent Levy on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/19/22
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial UpdateBusiness Wire • 05/19/22
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022Business Wire • 05/17/22
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual MeetingBusiness Wire • 05/02/22
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3Business Wire • 04/11/22